Racial, Ethnic Differences Seen for Benefits of Antihyperglycemic Agents
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Sept. 28, 2023 -- There are racial/ethnic differences in the cardiorenal effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP1-RAs) in patients with type 2 diabetes, according to a review published online Sept. 21 in the Journal of the Royal Society of Medicine.
Setor K. Kunutsor, M.D., Ph.D., from University of Leicester in the United Kingdom, and colleagues conducted a systematic literature review and meta-analysis to compare racial/ethnic as well as regional pattern effects for SGLT2is and GLP1-RAs on cardiovascular disease (CVD) and renal outcomes in patients with type 2 diabetes.
Based on 14 included trials, the researchers found that the risk for major adverse cardiovascular events (MACE) varied with SGLT2is by race (White: hazard ratio [HR], 0.92; Asian: HR, 0.69; Hispanic/Latino: HR, 0.70) versus placebo. Similar results were seen for GLP1-RAs versus placebo (HRs, 0.88, 0.76, and 0.82, respectively). For other cardiorenal outcomes, SGLT2is reduced the risk in White and Asian populations, except for heart failure hospitalizations in Asians. There were no effects found in Black populations except for a reduced risk for heart failure hospitalizations by SGLT2i. The risk for composite CVD death/heart failure hospitalization was reduced with SGLT2-Is in North America and Europe, while GLP1-RAs cut the risk for MACE in Europe. Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) certainty of evidence ranged from moderate to high.
"Whether the differences are due to issues with underrepresentation of Black populations and low statistical power or racial/ethnic variations in the pharmacokinetics, pharmacodynamics, and safety of SGLT2-Is and GLP1-RAs needs further investigation," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Prevalence of Skin Cancer Varies for Sexual Minority, Heterosexual Adults
FRIDAY, July 19, 2024 -- With respect to their lifetime prevalence of skin cancer, sexual minority (SM) adults differ across racial and ethnic groups and among males and females...
Concussions in Children Less Likely to Be Related to Sport
FRIDAY, July 19, 2024 -- For children aged 5 through 12 years with concussion, recreation-related concussion (RRC) and non-sport or recreation-related concussion (non-SRRC) occur...
Neighborhood Disadvantage Metrics Tied to Stress Genes in Prostate Cancer
FRIDAY, July 19, 2024 -- Expression of several stress-related genes in prostate tumors is elevated among men residing in disadvantaged neighborhoods, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.